Conference Call with Torrent Pharmaceuticals Management and Analysts on Q1FY26 Performance and Outlook. Listen to the full earnings transcript.
Pharmaceuticals company Torrent Pharmaceuticals announced Q1FY26 results Revenue at Rs 3,178 crore; grew by 11% YoY India revenues at Rs 1,811 crore were up by 11% led by outperformance in focus therapies. Brazil revenues at Rs 218 crore, were up by 11%. Germany revenues at Rs 308 crore, were up by 9% US business revenues at Rs 308 crore, were up by 19%. Op. EBITDA at Rs 1,032 crore, up by 14% YoY Op. EBITDA margin at 32.5%; Gross Margin: 76% Includes acquisition related one-off expenses of Rs 15 crore. Op. EBITDA adjusted for these one-offs is 1,047 crore, with a margin of 32.9% Net Profit after tax at Rs 548 crore, up by 20% YoY. R&D; spend stood at Rs 157 crore compared to Rs 135 crore up 16% Result PDF